UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Hadi, M. [1 ]
Swinburn, P. [1 ]
de Freitas, H. M. [1 ]
Ito, T. [2 ]
机构：
[1] Mapi Grp, London, England
[2] Janssen Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.242
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM175
引用
收藏
页码：A389 / A389
页数：1
相关论文
共 50 条
  • [41] Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort
    Maouche, Nadjoua
    Srinivasan, Anandagopal
    Leary, Heather
    Collings, Freya
    Tseu, Bing
    Vallance, Grant D.
    Ramasamy, Karthik
    Kothari, Jaimal
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, : 299 - 304
  • [42] DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Lakshman, A.
    Abeykoon, J.
    Kumar, S.
    Rajkumar, V.
    Kourelis, T.
    Buadi, F.
    Dingli, D.
    Martha, L.
    Gonsalves, W.
    Dispenzieri, A.
    Kyle, R.
    Lin, Y.
    Go, R.
    Warsame, R.
    Hobbs, M.
    Fonder, A.
    Hwa, Y.
    Hayman, S.
    Russell, S.
    Leung, N.
    Gertz, M.
    Kapoor, P.
    HAEMATOLOGICA, 2017, 102 : 508 - 508
  • [43] Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
    Chanan-Khan, Asher
    Wolf, Jeffrey
    Gharibo, Mecide
    Jagannath, Sundar
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Manfredi, Debbie
    Lee, Kelvin P.
    Miller, Kena C.
    Guild, Robin
    Zildjian, Sybil
    Qin, Albert
    O'Leary, James
    Vescio, Robert
    BLOOD, 2009, 114 (22) : 1126 - 1126
  • [44] ADJUSTED COMPARISON OF DARATUMUMAB MONOTHERAPY VERSUS REAL-WORLD HISTORICAL CONTROL DATA FROM THE CZECH REPUBLIC IN HEAVILY PRE-TREATED AND HIGHLY REFRACTORY MULTIPLE MYELOMA PATIENTS
    Diels, J.
    Gatopoulou, X.
    Besson, H.
    Vesela, S.
    Hajek, R.
    Jarkovsky, J.
    Ito, T.
    VALUE IN HEALTH, 2016, 19 (07) : A711 - A711
  • [45] Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
    Hultcrantz, Malin
    Anderson, Larry D., Jr.
    Anwer, Faiz
    Gasparetto, Cristina
    Kocoglu, Mehmet H.
    Lichtman, Eben I.
    Mo, Clifton
    Niesvizky, Ruben
    Lewis, Eric
    Li, Hong
    Paul, Sofia
    Petrone, Stephanie
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S440
  • [46] "Ethinylestradiol" is beneficial for postmenopausal advanced breast cancer patients heavily pre-treated with endocrine agents
    Iwase, H.
    Yamamoto, Y.
    Murakami, K-I
    Yamamoto-Ibusuki, M.
    Tomita, S.
    Omoto, Y.
    CANCER RESEARCH, 2012, 72
  • [47] Effective Panitumumab Treatment in Patients with Heavily Pre-treated Metastatic Colorectal Cancer: A Case Series
    Tzovaras, Alexandros A.
    Karagiannis, Athanassios
    Margari, Charalambia
    Barla, Georgia
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2011, 31 (03) : 1033 - 1037
  • [48] Daratumumab in heavily pre-treated patients: a single centre experience from the East of England.
    Sparksman, D.
    Cunningham, J.
    Bowles, K.
    Gomez, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 178 - 178
  • [49] Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer: "Real world" experience
    Sanganalmath, P.
    Purohit, K.
    Winter, M.
    Horsman, J.
    Ramakrishnan, S.
    Hatton, M.
    Lee, C.
    Dunn, K.
    Din, O.
    Coleman, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S181 - S182
  • [50] Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients
    Hutt, Daphna
    Bielorai, Bella
    Baturov, Bella
    Z'orbinski, Inna
    Ilin, Natalia
    Adam, Etai
    Itzhaki, Orit
    Besser, Michal J.
    Toren, Amos
    Jacoby, Elad
    TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (04)
12345